Jan 30, 2020

Organizational and Personnel Changes

TOKYO, January 30, 2020 -- Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced today the following organizational changes, effective April 1, 2020, and personnel changes, effective March 30 and April 1, 2020.

[Details of Organizational Changes]
Effective April 1, 2020
1. Abolition of Secretarial Dept. and reorganization of secretarial function

To enable efficient and flexible executive support, Secretarial Dept. will be integrated into General Affairs Dept., where Secretarial Office will be newly established. In addition, functions related to executive compensation will be transferred from Secretarial Dept. to Human Resources Management Dept. in order to integrate operation of the executive compensation system (directors and executive officers) and the personnel systems.

2. Abolition of PV & Safety Science Dept., and reorganization into two new departments (Drug Safety Div.)

To establish a safety strategy function capable of handling various new businesses, PV & Safety Science Dept. will be abolished and replaced by Safety Strategy Dept. and Pharmacovigilance Dept., which are newly established with the following aims.

  • Safety Strategy Dept.: to strengthen the safety science function
  • Pharmacovigilance Dept.: to improve efficiency and quality of the individual case safety report/the adverse drug reaction management

3. Renaming of Business Assessment Dept. (Project & Lifecycle Management Unit)

Business Assessment Dept. will be renamed Business Insights & Strategy Dept. in order to describe the department’s roles and mission more accurately and to ensure consistency with its counterpart at Roche while the Company will streamline and strengthen functions to capture business insights and create business strategies for in-house projects in early stages of development.

[Details of Personnel Changes]
Effective March 30, 2020

Directors

NameNew ResponsibilitiesCurrent Responsibilities
Tatsuro Kosaka Representative Director, Chairman
Chief Executive Officer (CEO)
Supervisory responsibility for Corporate Planning, Business Development, External Affairs, and Foundation Medicine
Representative Director, President
CEO
Supervisory responsibility for External Affairs, Pharmaceutical Technology, and Marketing & Sales
Osamu Okuda Representative Director, President
Chief Operating Officer (COO)
Supervisory responsibility for Project & Lifecycle Management, Regulatory & Quality Management, Clinical Development, Pharmaceutical Technology, Drug Safety, Medical Affairs, and Marketing & Sales
Co-Head of Project & Lifecycle Management Unit
Executive Vice President
Supervisory responsibility for Project & Lifecycle Management (Marketing), Foundation Medicine, Corporate Planning, and Business Development
Co-Head of Project & Lifecycle Management Unit
Mariko Momoi Director -
  • Osamu Nagayama is scheduled to retire from Representative Director, Chairman as of March 30, 2020 and to be appointed as Honorary Chairman.
  • Yasuo Ikeda is scheduled to retire from Director as of March 30, 2020.
  • The appointment of Osamu Okuda and Mariko Momoi as Directors is subject to approval at the 109th Annual General Meeting of Shareholders, which is scheduled to be convened on March 30, 2020.

Executive officer

NameNew ResponsibilitiesCurrent Responsibilities
Yasushi Ito Executive Vice President
Co-Head of Project & Lifecycle Management Unit
Executive Vice President
Supervisory responsibility for Project & Lifecycle Management (R&D), Regulatory & Quality Management, Clinical Development, Drug Safety, and Medical Affairs
Co-Head of Project & Lifecycle Management Unit

Audit & Supervisory Board Member

NameNew ResponsibilitiesCurrent Responsibilities
Kenichi Masuda Audit & Supervisory Board Member -
  • The appointment of Kenichi Masuda as Audit & Supervisory Board Member is subject to approval at the 109th Annual General Meeting of Shareholders, which is scheduled to be convened on March 30, 2020.
  • Hisashi Hara is scheduled to retire from Audit & Supervisory Board Member as of March 30, 2020.

Effective April 1, 2020

Director

NameNew ResponsibilitiesCurrent Responsibilities
Osamu Okuda Representative Director, President
COO
Supervisory responsibility for Project & Lifecycle Management, Regulatory & Quality Management, Clinical Development, Pharmaceutical Technology, Drug Safety, Medical Affairs, and Marketing & Sales
Representative Director, President
COO
Supervisory responsibility for Project & Lifecycle Management, Regulatory & Quality Management, Clinical Development, Pharmaceutical Technology, Drug Safety, Medical Affairs, and Marketing & Sales
Co-Head of Project & Lifecycle Management Unit

Executive officers

NameNew ResponsibilitiesCurrent Responsibilities
Shinya Unno Deputy President
Supervisory responsibility for Human Resources Management, Human Capital Development, Legal, Intellectual Property, and General Affairs
In charge of General Affairs Dept.
Executive Vice President
Supervisory responsibility for Human Resources Management, Human Capital Development, Legal, Intellectual Property, General Affairs, and Secretarial
General Manager of Human Resources Supervisory Div.
In charge of General Affairs Dept. and Secretarial Dept.
Toshiaki Itagaki Executive Vice President
Chief Financial Officer (CFO)
Supervisory responsibility for Finance & Accounting, Corporate Communication, Purchasing, Digital Strategy, and IT Solution
General Manager of Finance Supervisory Div.
Executive Vice President
CFO
Supervisory responsibility for Finance & Accounting, Corporate Communication, Purchasing, Digital Strategy, and IT Solution
General Manager of Finance Supervisory Div. and General Manager of Finance & Accounting Dept.
Tetsuya Yamaguchi Senior Vice President
General Manager of Corporate Planning Dept. and Head of Foundation Medicine Unit
Vice President
General Manager of Business Development Dept.
Mark Noguchi Senior Vice President
General Manager of Business Development Dept.
-
Minoru Watanabe Vice President
Head of Project & Lifecycle Management Unit
Vice President
General Manager of Corporate Planning Dept. and Head of Foundation Medicine Unit
Shinji Hidaka Vice President
General Manager of Marketing &
Sales Div.
Vice President
General Manager of Medical Affairs Div.
Yoshiyuki Yano Vice President
General Manager of Human Resources Supervisory Div. and General Manager of Human Resources Management Dept.
Vice President
General Manager of Human Resources Management Dept.
Junichi Nezu Vice President
General Manager of Research Div.
Associate Vice President
General Manager of Research Div.
Tsukasa Kusano Vice President
General Manager of Clinical Development Div.
Associate Vice President
Deputy General Manager of
Marketing & Sales Div.
Kaori Ouchi Vice President
General Manager of Medical Affairs Div. and Department Manager of Medical Science Dept., Medical Affairs Div.
Department Manager of Medical Science Dept., Medical Affairs Div.
Masatoshi Takada Vice President
Head of Kansai Regional
Management Office, Marketing &
Sales Div.
Associate Vice President
Head of Kansai Regional
Management Office, Marketing &
Sales Div.
  • Yasushi Ito is scheduled to retire from Executive Vice President as of March 31, 2020.
  • Toshihiko Komori, Hisanori Takanashi, Tsunanori Sato, and Kouichi Nishikawa are scheduled to retire from Vice Presidents as of March 31, 2020. Hisanori Takanashi is scheduled to be appointed as an Advisor (full-time).

Please see the PDF file about other personnel changes.

Contact:

  • For Media
  • Chugai Pharmaceutical Co., Ltd.
  • Media Relations Group, Corporate Communications Dept.,
  • Tomoko Shimizu
  • Tel: +81-3-3273-0881
  • E-mail: pr@chugai-pharm.co.jp
  • For Investors
  • Chugai Pharmaceutical Co., Ltd.
  • Investor Relations Group, Corporate Communications Dept.,
  • Toshiya Sasai
  • Tel: +81-3-3273-0554
  • E-mail: ir@chugai-pharm.co.jp
  • Like
  • Tweet
  • LINE it!
  • E-mail
Back to top